Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
10.07. | Insulet, Medtronic laud debut of first Barbie with Type 1 diabetes | ||
10.07. | Pfizer, Astellas boost case for Xtandi in early-stage prostate cancer with combo survival win | ||
10.07. | Pressuring Merck's Gardasil, China's home-made 9-valent HPV vaccine priced at 60% discount | ||
10.07. | Woven sews up Boundless buyout to add medical marketing services | ||
10.07. | FDA releases 'initial batch' of more than 200 drug rejection letters | ||
10.07. | AbbVie pays $700M upfront for trispecific rival to J&J, Pfizer in blood cancer | ||
10.07. | New cadence at Jazz as Renee Gala replaces 16-year CEO Bruce Cozadd | ||
09.07. | Gilead partners with the Global Fund to support Yeztugo access strategy on heels of FDA nod | ||
09.07. | Merck boosts respiratory portfolio with $10B acquisition of Verona Pharma and potential COPD blockbuster Ohtuvayre | ||
09.07. | Granules recalls 33K bottles of blood pressure med in US, citing failed stability tests | ||
09.07. | Trump renews 200% tariff threat on pharmaceuticals, indicates plan for grace period | ||
09.07. | Novo keeps China manufacturing investments rolling with $112M for new quality testing lab in Tianjin | ||
09.07. | Respiratory pharma royalty rally around rural COPD education and support drive | ||
08.07. | Biopharma layoffs for first half of the year jump 32% YOY | ||
08.07. | Advocacy groups, health networks and others back bill seeking to nix 'interchangeable' biosim tag | ||
08.07. | Southwest Airlines sues dozens of generic drugmakers for alleged price-fixing scheme | ||
08.07. | UCB extends Bimzelx ad campaign in wake of hidradenitis suppurativa approval | ||
08.07. | Novartis' malaria drug for babies wins world-first approval | ||
08.07. | Achieve sparks up Omnicom pact, securing agency support for nicotine dependence drug launch | ||
07.07. | Novo's Wegovy retakes top TV spending spot in June, edging out AbbVie, J&J immunology ads | ||
07.07. | HIV drugmaker Theratechnologies agrees to $254M buyout by CDMO Future Pak | ||
07.07. | Dizal to challenge J&J with FDA approval for lung cancer drug Zegfrovy | ||
07.07. | Amid $15B AstraZeneca partnership rumor, Summit needs $7.7B upfront to excite investors: analyst | ||
07.07. | KalVista bounces back from FDA delay with approval for oral rare disease med Ekterly | ||
07.07. | CDMO BioSpring beefs up nucleic acid production with new API plant |